Inogen (NASDAQ:INGN – Get Free Report)‘s stock had its “hold” rating reaffirmed by analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports.
Separately, StockNews.com raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on Inogen
Inogen Stock Up 17.2 %
Hedge Funds Weigh In On Inogen
Several hedge funds and other institutional investors have recently added to or reduced their stakes in INGN. Meeder Asset Management Inc. bought a new stake in shares of Inogen during the 2nd quarter valued at about $30,000. CWM LLC grew its stake in Inogen by 2,185.9% in the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock worth $54,000 after buying an additional 6,339 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Inogen in the 1st quarter worth $81,000. Pitcairn Co. purchased a new stake in shares of Inogen during the 1st quarter valued at $86,000. Finally, Oppenheimer Asset Management Inc. purchased a new position in Inogen in the first quarter worth $121,000. 89.94% of the stock is currently owned by hedge funds and other institutional investors.
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
- Five stocks we like better than Inogen
- How to Read Stock Charts for Beginners
- California Resources Stock Could Be a Huge Long-Term Winner
- What Does a Stock Split Mean?
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- 3 Best Fintech Stocks for a Portfolio Boost
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.